Clinical Trial: Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A RANDOMIZED CONTROLLED STUDY OF ITRACONAZOLE IN CHRONIC CAVITARY PULMONARY ASPERGILLOSIS
Brief Summary: The purpose of this study is to determine whether there itraconazole is effective in the treatment of chronic cavitary pulmonary aspergillosis
Detailed Summary: The role of itraconazole is still not clear in the treatment of chronic cavitary pulmonary aspergillosis(CCPA). Some studies have shown a beneficial role of itraconazole in reducing hemoptysis. So the present study is aimed at analyzing the role of itraconazole in CCPA.
Sponsor: Postgraduate Institute of Medical Education and Research
Current Primary Outcome: clinical improvement in cough and hemoptysis [ Time Frame: 6 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Radiological response of CCPA to itraconazole [ Time Frame: 6 months ]
- Complete response- It is defined as complete disappearance of the aspergilloma.
- Partial response- It is defined as 30% decrease in the sum of the longest diameters of all the lesions.
- Progressive disease- It is defined as appearance of any new lesions or >20% increase in the sum of the longest diameters of all measurable lesions.
- Stable disease- Shrinkage or growth of CCPA that does not meet any of these criteria
Original Secondary Outcome: Same as current
Information By: Postgraduate Institute of Medical Education and Research
Dates:
Date Received: December 6, 2010
Date Started: July 2010
Date Completion:
Last Updated: February 18, 2012
Last Verified: November 2010